AZD 5213

Drug Profile

AZD 5213

Alternative Names: AZD5213

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Nootropics; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Diabetic neuropathies; Gilles de la Tourette's syndrome; Mild cognitive impairment

Most Recent Events

  • 01 May 2015 AstraZeneca completes a phase II trial for painful Diabetic neuropathies in USA (NCT01928381)
  • 01 Feb 2015 AstraZeneca completes a phase II trial in Tourette's syndrome (in adolescents) in USA (NCT01904773)
  • 01 Nov 2013 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top